Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -160.85% is in line with its 5-year average of -152.10%, around the middle of its 5-year range (-338.71%–-29.38%).
As of the fiscal period ended Tuesday, June 30, 2026. 17.27% below its 12-month average of -137.17%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -160.85%.
RETURN ON EQUITY (ROE)
-160.85%
RETURN ON EQUITY (ROE) AVG TTM
-137.17%
RETURN ON EQUITY (ROE) AVG 3Y
-194.30%
RETURN ON EQUITY (ROE) AVG 5Y
-152.10%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-17.27%
CURRENT VS 3Y AVG
+17.22%
CURRENT VS 5Y AVG
-5.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
-290.42%
vs the sector median at left
NeuroPace, Inc.
Market Cap
$446.29M
Return on Equity (ROE)
-160.85%
TTM Avg
-137.17%
3Y Avg
-194.30%
5Y Avg
-152.10%
Market Cap
$444.98M
Return on Equity (ROE)
-97.92%
TTM Avg
-59.21%
3Y Avg
-49.84%
5Y Avg
-46.25%
Market Cap
$444.69M
Return on Equity (ROE)
-16.43%
TTM Avg
-26.04%
3Y Avg
-38.16%
5Y Avg
-45.00%
Market Cap
$441.97M
Return on Equity (ROE)
-52.56%
TTM Avg
-31.09%
3Y Avg
-101.75%
5Y Avg
-86.54%
Market Cap
$457.04M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$433.90M
Return on Equity (ROE)
-0.01%
TTM Avg
-61.70%
3Y Avg
-96.25%
5Y Avg
-81.28%
Market Cap
$432.39M
Return on Equity (ROE)
-38.32%
TTM Avg
-35.34%
3Y Avg
12.60%
5Y Avg
10.50%
Market Cap
$430.17M
Return on Equity (ROE)
-70.24%
TTM Avg
-381.56%
3Y Avg
-217.03%
5Y Avg
-155.40%
Market Cap
$428.59M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $446.29M | -160.85% | -137.17% | -194.30% | -152.10% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $444.98M | -97.92% | -59.21% | -49.84% | -46.25% |
| Ovid Therapeutics Inc. (OVID)vs › | $444.69M | -16.43% | -26.04% | -38.16% | -45.00% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $441.97M | -52.56% | -31.09% | -101.75% | -86.54% |
| NRC Health (NRC)vs › | $457.04M | 89.43% | 81.07% | 67.39% | 61.90% |
| Assembly Biosciences, Inc. (ASMB)vs › | $433.90M | -0.01% | -61.70% | -96.25% | -81.28% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $432.39M | -38.32% | -35.34% | 12.60% | 10.50% |
| Editas Medicine, Inc. (EDIT)vs › | $430.17M | -70.24% | -381.56% | -217.03% | -155.40% |
| NeoGenomics, Inc. (NEO)vs › | $428.59M | -6.60% | -10.82% | -11.36% | -7.59% |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | -56.26% | -59.48% | -54.76% | -34.52% |
ROE
-160.9%
ROA
-19.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -160.85% |
| 2026-03-31 | -149.20% |
| 2025-12-31 | -112.79% |
| 2025-09-30 | -129.53% |
| 2025-06-30 | -133.46% |
| 2025-03-31 | -102.21% |
| 2024-12-31 | -338.71% |
| 2024-09-30 | -285.97% |
| 2024-06-30 | -302.44% |
| 2024-03-31 | -219.69% |
| 2023-12-31 | -159.56% |
| 2023-09-30 | -231.63% |
| 2023-06-30 | -199.90% |
| 2023-03-31 | -167.32% |
| 2022-12-31 | -135.38% |
| 2022-09-30 | -107.42% |
| 2022-06-30 | -81.14% |
| 2022-03-31 | -61.65% |
| 2021-12-31 | -49.09% |
| 2021-09-30 | -36.72% |
| 2021-06-30 | -29.38% |
